CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice - Clinical implications for CCR5 inhibition as antiretroviral therapy [1]

Hepatology

Volumn 43, Issue 4, 2006, Pages 879-

  Mauss, Stefan ^a   Puoti, Massimo ^b  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APLAVIROC; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; INTERFERON; MARAVIROC;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG INHIBITION; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LETTER; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; MORTALITY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; T LYMPHOCYTE;

ANIMALS; ANTI-RETROVIRAL AGENTS; CONCANAVALIN A; HEPATITIS, TOXIC; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, CCR5; T-LYMPHOCYTES;

EID: 33645965256     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21148     Document Type: Letter

References (7)

1. Moreno C, Gusto T, Nicaise C, Quertinmot E, Nagy N, Parmentier M, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. HEPATOLOGY 2005;42:854-862.
2. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman A, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-1172.
3. Schuermann D, Pechardschek C, Rouzier R, Nougarede R, Faetkenheuer G, Ochlast I, et al. SCH 417690: antiviral activity of a potent new receptor antagonist. Third IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 24-27, 2005. Abstract TuOa0205.
4. Nichols WG, Steel HM, Bonny TM, Min SS, Curtis L, Kabeya K, et al. Hepatotoxicity observed in clinical trials of aplaviroc (APL 873140). Tenth European AIDS Conference. November 17-20 2005. Dublin, www.eacs-conference2005.com.
5. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. HEPATOLOGY 2003;38:1468-1476.
6. Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U. CC-chemokine receptor 5 (CCR5) in hepatitis C - at the crossroads of the antiviral immune response? J Antimicrob Chemother 2004;53:895-898.
7. Galvani AP, Novembre J. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect 2005;7:302-309.